SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (12921)1/1/1998 10:41:00 AM
From: Henry Niman  Respond to of 32384
 
TD, Many companies have an anti-angiogeneis programs, including LGND. The most advanced compoound is BBIOY's Maristat program. The company has a huge market cap largely based on the one drug (but it is trials for several cancers). AGPH had a MMPI (matrix metalloprotein inhibitor) program with Roche, but it was recently terminated with AGPH retaining rights. LGND's program includes MMPIs obtained in the GLYC acquisition. The approach has been around for a couple of decades, but there is no effective approved compound at this time.



To: Arthur Radley who wrote (12921)1/1/1998 10:44:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
TD, Although Panretin oral is in an advanced trial for KS, part of the protocol involves looking for improvement in immunological parameters. This large program is being sponsored by the AIDS Consortium of the govenment. If Panretin does improve these parameters, then it would have applications for all HIV+ patients, not just those with KS.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News